Previous 10 | Next 10 |
ElectroCore (NASDAQ: ECOR ) initiated with Outperform rating and $19 (222% upside) at Noble Capital. More news on: electroCore, Inc., Sarepta Therapeutics, Inc., Flexion Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
MannKind ( MNKD ) hosted its Q1 quarterly call on May 7th. The company highlighted the results from the business, and as expected, presented the highlights in a manner that accentuated the positives. First things first, I overestimated gross revenue and net revenue. I underestimated the sp...
United Therapeutics ( UTHR -1.6% ) and development partner DEKA Research & Development Corp. announce FDA 510(k) clearance of the Unity Subcutaneous Delivery System for Remodulin (treprostinil), branded as the RemUnity system. More news on: United Therapeutics Corporation, Healthca...
RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H. , May 7, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of 510(k) clearance by the U.S. Food and Drug Administration (FDA) for the Unity Subcutaneous ...
MannKind ( MNKD ) will host its Q1 quarterly conference call on Tuesday, May 7th at 9:00 AM Eastern. The Q1 call will precede the annual shareholder meeting by about a week and that could make things pretty interesting. Typically, management of any company on a quarterly call controls the ...
United Therapeutics Corporation (UTHR) Q1 2019 Results Earnings Conference Call May 01, 2019, 9:00 am ET Company Participants James Edgemond - Chief Financial Officer Martine Rothblatt - Chairman, Chief Executive Officer Michael Benkowitz - President, Chief Operating Officer C...
United Therapeutics ( UTHR ) Q1 results : Revenues: $362.6M (-6.8%). More news on: United Therapeutics Corporation, Healthcare stocks news, Earnings news and commentary, Read more ...
United Therapeutics (NASDAQ: UTHR ): Q1 Non-GAAP EPS of $3.58 beats by $0.97 ; GAAP EPS of -$11.32. More news on: United Therapeutics Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , May 1, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2019. "I'm very pleased to report that last quarter we helped more pulmon...
SILVER SPRING, Md. , April 29, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that its collaborator, XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (STO: XVIVO), has received Premarket Approval (PMA) from the U.S. Food and Drug Administratio...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...